Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (11290)	8/17/1999 8:48:00 AM
From: Cacaito	Respond to of 17367

"positive results from a 400-patient Phase II clinical trial in patients suffering hemorrhagic trauma (acute loss of blood). Preliminary analysis of the data showed a positive overall benefit in patients receiving Neuprex(tm) versus placebo for the primary endpoint in this study, defined as a reduced incidence of serious organ dysfunction, infections, and death. Product safety was also confirmed across the entire patient population." Only problem here is that the data came out ONE YEAR later in J.of Trauma. And only reduced infections (pneumonia) was the truth. This is fine for a phase II, not for a long, definitive phase III. They are using the FDA excuse. Most companies do put the preliminary out very early, before any FDA. Yes, the FDA wants details, they have to meet with FDA, nothing new. The only new thing here is the catastrophic Bloomberg "pr". The "pr" is what got to be clarify, a mess of their own. Please, stop accepting the FDA made me do it version.